These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 22521148)

  • 1. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.
    Cornwell BR; Salvadore G; Furey M; Marquardt CA; Brutsche NE; Grillon C; Zarate CA
    Biol Psychiatry; 2012 Oct; 72(7):555-61. PubMed ID: 22521148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
    Gilbert JR; Yarrington JS; Wills KE; Nugent AC; Zarate CA
    Int J Neuropsychopharmacol; 2018 Aug; 21(8):740-747. PubMed ID: 29668918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of intranasal ketamine in major depressive disorder.
    Lapidus KA; Levitch CF; Perez AM; Brallier JW; Parides MK; Soleimani L; Feder A; Iosifescu DV; Charney DS; Murrough JW
    Biol Psychiatry; 2014 Dec; 76(12):970-6. PubMed ID: 24821196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.
    Nugent AC; Wills KE; Gilbert JR; Zarate CA
    Psychiatry Res Neuroimaging; 2019 Jan; 283():64-66. PubMed ID: 30551012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression.
    Rivas-Grajales AM; Salas R; Robinson ME; Qi K; Murrough JW; Mathew SJ
    Int J Neuropsychopharmacol; 2021 May; 24(5):383-391. PubMed ID: 33249434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans.
    Zhuo C; Tian H; Li G; Chen M; Jiang D; Lin X; Xu Y; Wang W
    Brain Behav; 2019 Nov; 9(11):e01423. PubMed ID: 31617335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
    Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA
    J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous arketamine for treatment-resistant depression: open-label pilot study.
    Leal GC; Bandeira ID; Correia-Melo FS; Telles M; Mello RP; Vieira F; Lima CS; Jesus-Nunes AP; Guerreiro-Costa LNF; Marback RF; Caliman-Fontes AT; Marques BLS; Bezerra MLO; Dias-Neto AL; Silva SS; Sampaio AS; Sanacora G; Turecki G; Loo C; Lacerda ALT; Quarantini LC
    Eur Arch Psychiatry Clin Neurosci; 2021 Apr; 271(3):577-582. PubMed ID: 32078034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression.
    Su TP; Chen MH; Li CT; Lin WC; Hong CJ; Gueorguieva R; Tu PC; Bai YM; Cheng CM; Krystal JH
    Neuropsychopharmacology; 2017 Dec; 42(13):2482-2492. PubMed ID: 28492279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
    Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M
    J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine.
    Salvadore G; Cornwell BR; Sambataro F; Latov D; Colon-Rosario V; Carver F; Holroyd T; DiazGranados N; Machado-Vieira R; Grillon C; Drevets WC; Zarate CA
    Neuropsychopharmacology; 2010 Jun; 35(7):1415-22. PubMed ID: 20393460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.
    Machado-Vieira R; Yuan P; Brutsche N; DiazGranados N; Luckenbaugh D; Manji HK; Zarate CA
    J Clin Psychiatry; 2009 Dec; 70(12):1662-6. PubMed ID: 19744406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketamine Enhances Visual Sensory Evoked Potential Long-term Potentiation in Patients With Major Depressive Disorder.
    Sumner RL; McMillan R; Spriggs MJ; Campbell D; Malpas G; Maxwell E; Deng C; Hay J; Ponton R; Kirk IJ; Sundram F; Muthukumaraswamy SD
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2020 Jan; 5(1):45-55. PubMed ID: 31495712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
    Aust S; Gärtner M; Basso L; Otte C; Wingenfeld K; Chae WR; Heuser-Collier I; Regen F; Cosma NC; van Hall F; Grimm S; Bajbouj M
    Eur Neuropsychopharmacol; 2019 Apr; 29(4):529-538. PubMed ID: 30772118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid and sustained antidepressant effects of intravenous ketamine in treatment-resistant major depressive disorder and suicidal ideation: a randomized clinical trial.
    Zolghadriha A; Anjomshoaa A; Jamshidi MR; Taherkhani F
    BMC Psychiatry; 2024 May; 24(1):341. PubMed ID: 38714931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study.
    Li CT; Chen MH; Lin WC; Hong CJ; Yang BH; Liu RS; Tu PC; Su TP
    Hum Brain Mapp; 2016 Mar; 37(3):1080-90. PubMed ID: 26821769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
    Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
    Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
    Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
    J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
    J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.